Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Eli Lilly sued for age discrimination by U.S. agency EEOC

Published 09/26/2022, 07:18 PM
Updated 09/26/2022, 08:31 PM
© Reuters. FILE PHOTO: FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.  REUTERS/Mike Segar/File Photo

By Jonathan Stempel

(Reuters) - Eli Lilly (NYSE:LLY) and Co was sued on Monday by the U.S. Equal Employment Opportunity Commission, which accused the drugmaker of illegally refusing to hire older workers for sales representative jobs because of their age. The complaint said Lilly's violations began after Stephen Fry, its senior vice president for human resources and diversity, lamented during an April 2017 "Leadership Town Hall" that its sales force was skewed toward older workers, with 20% fewer "millennials" than the American workforce.

According to the EEOC, Fry suggested that the lack of millennials was a problem, and the Indianapolis-based company would target 40% "Early Career" hiring.

Managers then changed their hiring practices for sales representatives, sometimes requiring greater review and approval before extending offers to older candidates, even after some recognized that the 40% goal was illegal, the EEOC said. The target remained through 2021, it added.

Lilly, in a statement, denied the accusations and said it was "committed to fostering and promoting a culture of diversity and respect."

The lawsuit filed in Indianapolis federal court accused Lilly of violating the federal Age Discrimination in Employment Act.

It seeks to permanently enjoin future discrimination, obtain back pay and other damages for people not hired because of their age, and improve training for supervisors and managers.

"This case underscores the continued need for the EEOC to break down barriers to employment" for older Americans as they work longer and in larger numbers, Robert Weisberg, an EEOC lawyer who helped bring the case, said in a statement.

Lilly's top-selling product is Trulicity, a treatment for type 2 diabetes.

© Reuters. FILE PHOTO: FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.  REUTERS/Mike Segar/File Photo

On Aug. 11, Lilly said Fry would retire at the end of 2022 after more than 35 years at the company.

The case is EEOC v Lilly USA LLC, U.S. District Court, Southern District of Indiana, No. 22-01882.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.